NCT01892371 2025-04-06
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
25 trialsNCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04629443 2024-06-06
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
Servier
Phase 1/2 Completed
NCT03047993 2024-05-14
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT03701295 2023-10-18
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03072043 2022-01-24
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01926587 2021-06-16
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01155583 2020-11-16
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00946647 2020-08-04
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Novartis
Phase 1/2 Completed
NCT01193517 2020-04-15
Azacitidine and CAPOX in Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01983969 2020-01-27
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00895934 2019-05-23
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00387465 2019-05-09
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00766116 2019-02-18
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
University of California, San Diego
Phase 1/2 Completed
NCT01202877 2018-10-16
PKC412 and 5-Azacytidine
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00352001 2018-09-19
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00890929 2018-06-18
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Stanford University
Phase 1/2 Completed
NCT00748553 2017-07-26
VA
University of Utah
Phase 1/2 Completed
NCT01120834 2017-04-10
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT01038635 2017-02-10
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01254890 2016-05-06
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01016600 2015-09-07
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT00569010 2012-08-01
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1/2 Completed